ImmunityBio (IBRX)
(Real Time Quote from BATS)
$2.38 USD
0.00 (0.00%)
Updated Aug 7, 2025 09:58 AM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, ImmunityBio, Inc. has a market cap of $2.25B, which represents its share price of $2.38 multiplied by its outstanding shares number of 945.26M. As a mid-cap company, IBRX's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
IBRX 2.38 0.00(0.00%)
Will IBRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IBRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IBRX
ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
IBRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for IBRX
Decoding ImmunityBio Inc (IBRX): A Strategic SWOT Insight
ImmunityBio (IBRX) Receives Continuous Buy Rating from D. Boral Capital | IBRX Stock News
ImmunityBio GAAP EPS of -$0.10 beats by $0.01, revenue of $26.43M beats by $2.38M
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With ...
ImmunityBio (IBRX) Maintains Buy Rating with $30 Price Target | IBRX Stock News